Moderna Says mRNA Cancer Vaccine Reduces Melanoma's Return By 44%

An anonymous reader quotes a report from the Associated Press: The company said a possible melanoma vaccine it is studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically removed. The drugmakers said a combination of the vaccine and Merck's immunotherapy Keytruda led to a statistically significant improvement in survival before the cancer returned in patients with advanced melanoma. [...] Like Spikevax (the vaccine used to help protect against COVID-19), the potential skin cancer vaccine uses mRNA technology. It trains a patient's immune system to recognize and respond specifically to mutations in the DNA of the patient's tumor. In a mid-stage clinical trial involving 157 patients, researchers compared the vaccine-Keytruda combination with Keytruda alone. Keytruda, Merck's top seller, primes the body's immune system to detect and fight tumor cells. Regulators have approved it to treat several types of cancer. The patient group that took the potential vaccine and Keytruda saw a 44% reduction in the risk of death or the cancer returning, the companies said. The treatments continued for about a year in both groups unless the disease came back or side effects became too severe. Merck and Moderna expect to start a phase 3 study next year, and the companies say they intend to expand their approach to other tumor types.

Read more of this story at Slashdot.